Background Neurocognitive assessments have become integral to comprehensive neuro-
oncology care. Existing screening tools may be insensitive to cognitive changes caused by …

Approaches to classifying neuropsychological impairment after brain tumor vary according
to testing level (individual tests, domains, or global index) and source of reference (ie …

e13000 Background: Brief cognitive screening measures are often selected by clinicians
and researchers for brain tumor patients, primarily because of their ease of use. Currently …

Purpose of review A detailed characterization of the nature of neurocognitive impairment in
patients with brain tumors is provided, as well as considerations for clinical practice …

Background Gliomas are typically considered to cause relatively few neurological
impairments. However, cognitive difficulties can arise, for example during treatment, with …

Neuropsychological tests are increasingly being used as outcome measures in clinical trials
of brain tumor therapies. This study informs development of brief neurocognitive batteries for …

NeuroCogFX is a short yet comprehensive computer-based neuropsychological battery of
tests developed to investigate neurological patients for cognitive dysfunction after potentially …

Background Subjective cognitive function is an important outcome measure in oncology.
The Functional Assessment of Cancer Therapy—Brain (FACT-Br) is a quality of life (QoL) …

This study presents the first validation of the Brief Cognitive Status Exam (BCSE) against two
other screening tools for cognitive impairment in patients with intracranial tumors. 58 …

Objective: Neuropsychological literature reports varying prevalence of cognitive impairment
within patient populations, despite assessment with standardized neuropsychological tests …